Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes
Clinical and Experimental Immunology, Volume 146, No. 1, Year 2006
Notification
URL copied to clipboard!
Description
Autoantibodies to insulin (IAA) are one of the first markers of the autoimmune process leading to type 1 diabetes (T1D). While other autoantibodies in T1D have been studied extensively, relatively little is known about IAA and their binding specificities, especially after insulin treatment is initiated. We hypothesize that insulin antibodies (IA) that develop upon initiation of insulin treatment differ in their epitope specificities from IAA. We analysed insulin antibody binding specificities in longitudinal samples of T1D patients (n = 49). Samples were taken at clinical diagnosis of disease and after insulin treatment was initiated. The epitope specificities were analysed using recombinant Fab (rFab) derived from insulin-specific monoclonal antibodies AE9D6 and CG7C7. Binding of radiolabelled insulin by samples taken at onset of the disease was significantly reduced in the presence of rFab CG7C7 and AE9D6. rFab AE9D6 competed sera binding to insulin significantly better than rFab CG7C7 (P = 0.02). Binding to the AE9D6-defined epitope in the initial sample was correlated inversely with age at onset (P = 0.005). The binding to the AE9D6-defined epitope increased significantly (P < 0.0001) after 3 months of insulin treatment. Binding to the CG7C7-defined epitope did not change during the analysed period of 12 months. We conclude that epitopes recognized by insulin binding antibodies can be identified using monoclonal insulin-specific rFab as competitors. Using this approach we observed that insulin treatment is accompanied by a change in epitope specificities in the emerging IA. © 2006 British Society for Immunology.
Authors & Co-Authors
Hall, Tyler R.
United States, Seattle
University of Washington
Thomas, James W.
United States, Nashville
Vanderbilt University
Padoa, Carolyn J.
South Africa, Johannesburg
University of the Witwatersrand
Törn, Carina
Sweden, Lund
Skånes Universitetssjukhus
Landin-Olsson, Mona
Sweden, Lund
Skånes Universitetssjukhus
Örtqvist, Eva
Sweden, Stockholm
Karolinska Institutet
Hampe, Christiane Susanne
United States, Seattle
University of Washington
Statistics
Citations: 7
Authors: 7
Affiliations: 5
Identifiers
Doi:
10.1111/j.1365-2249.2006.03178.x
ISSN:
00099104
e-ISSN:
13652249
Research Areas
Noncommunicable Diseases
Study Design
Cohort Study